fiercebiotechSeptember 18, 2018
Tag: blood test , immunotherapy , machine learning
Cancer blood test company Epic Sciences brought in $52 million to advance its suite of liquid biopsies, which use computer vision and machine learning to identify circulating tumor cells while characterizing the body’s immune response at the same time, toward regulatory approval.
The platform, dubbed No Cell Left Behind, aims to predict individual patients’ responses to different cancer therapies and combinations, as well as to detect early drug resistance. Epic also plans to use the new funds to help integrate its tests with electronic health records and big data analytics to establish patterns in cancer cell evolution, drug selection and clinical outcomes.
The series E round was led by Blue Ox Healthcare Partners, with participation from Deerfield Management and new partner Varian Medical Systems. Previous investors, including Altos Capital Partners, Genomic Health, Domain Associates, VI Ventures, Alexandria Venture Investments and Sabby Management, also returned to back the San Diego-based company.
-----------------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: